Peregrine Pharmaceuticals, Inc. (PPHM) Appoints New Head of Medical Oncology, Advances Randomized Phase II Trials
Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, announced the appointment of Kerstin B. Menander, M.D., Ph.D. as the head of medical oncology. During Dr. Menander’s 30-career, she has led various oncology programs in senior positions at Abbott Laboratories and a variety of other clinical-stage biopharmaceutical companies. She has shown support for 15 approvals in the U.S and Europe, which include Lupron(R), the leading therapy treatment for prostate cancer. At Peregrine, Dr. Menander will be supporting multiple advancing randomized Phase II trial for the company’s main product bavituximab, which is under evaluation in combination with chemotherapy for non-small cell lung…